{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PD-1+inhibitor", "query": { "intervention": "PD-1 inhibitor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 431, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PD-1+inhibitor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T11:24:31.522Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04041310", "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "GAd-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP low dose", "type": "BIOLOGICAL" }, { "name": "GAd-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP high dose", "type": "BIOLOGICAL" }, { "name": "GAd20-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "MVA-209-FSP, RP2D", "type": "BIOLOGICAL" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nouscom SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-10-21", "completion_date": "2026-10-30", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041310" }, { "nct_id": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Limited Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "BMS-986489", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-03-11", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 34, "location_summary": "Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06773910" }, { "nct_id": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "margetuximab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tebotelimab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2019-09-30", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 28, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082364" }, { "nct_id": "NCT03083808", "title": "Phase II Trial of Continuation Therapy in Advanced NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Greg Durm, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2017-03-20", "completion_date": "2022-03-03", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03083808" }, { "nct_id": "NCT03606174", "title": "A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma Ureter", "Urothelial Carcinoma of the Renal Pelvis and Ureter", "Urothelial Carcinoma Urethra" ], "interventions": [ { "name": "Sitravatinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2018-09-11", "completion_date": "2022-08-22", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 36, "location_summary": "Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606174" }, { "nct_id": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Stereotactic ablative radiotherapy (SAR)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-05-17", "completion_date": "2020-06-24", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03158883" }, { "nct_id": "NCT07319195", "title": "Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Intratumoral Mitazalimab", "type": "DRUG" }, { "name": "Intratumoral Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer Zhang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-04-27", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07319195" }, { "nct_id": "NCT04493203", "title": "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yana Najjar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-12-18", "completion_date": "2025-04-12", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493203" }, { "nct_id": "NCT06385262", "title": "TOP 2301: Neoadjuvant Chemo for NSCLC", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2025-03-17", "completion_date": "2029-10-30", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385262" }, { "nct_id": "NCT03884556", "title": "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "TTX-030", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trishula Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-04-10", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-12T11:24:31.522Z", "location_count": 16, "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 12 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03884556" } ] }